NRSG 2350 Exam 2 Meds Review exam fully
solved & updated 2025-2026(latest version verified
for accuracy)
ferrous sulfate - answer--WHY: treatment for IDA
MOA: Replaces serum iron concentration for hemoglobin production
ADE: constipation, darkened stool, staining of teeth, NVD
CI: children toxicity, hemochromatosis, peptic ulcers
D-D: antacids, tetracyclines, ascorbic acid
cyanocobalamin (synthetic form of B12) - answer--WHY: pernicious
anemia, essential for cell growth and division - necessary for myelin
sheath
MOA: replacement of essential vitamin B12
ADE: NVD, injection site reaction, itching
CI: alleries, thickened blood
folic acid (vitamin B9) - answer--WHY: folic acid deficiency anemia,
prophylaxis during pregnancy (prevent neural tube defects)
MOA: water soluble, essential for cell growth and division, replacement
of essential vitamin
ADE: NVD, no known because it is something we already have
CI: allergy, methotrexate
,hydroxyurea (droxia) - answer--WHY: sickle cell anemia, increase fetal
hemoglobin in the bone marrow
MOA: increase fetal hemoglobin in the bone marrow
ADE: NVD, HA, disorientation, chills, increase risk of cancer, bone
marrow suppression
CI: allergy, severe anemia / leukopenia, pregnancy, liver/kidney
impairment
D-D: warfarin, uricosuric agents
epoetin alfa (Epogen), erythropoiesis stimulating agent - answer--WHY:
treat anemia of chronic disease, reduce the need for pRBC transfusions
MOA: stimulates bone marrow to make more RBCs (erythropoiesis)
ADE: seizures, HA, dizzy, NVD, HTN, edema, chest pani
CI: uncontrolled HTN
D-D: do not mix with other drugs
antihemophilic - answer--WHY: replace factor VIII in patients with
hemophilia A, prevent blood loss from injury, surgery or to treat
disorder
MOA: replaced blood clotting factors - genetically missing or low
ADE: HA, flushing, chills, lethargy, NV, site reaction
CI: allergy, inhibitors of factor VIII, factor IX with liver disease, lactation
, antiocoagulants - answer---prevents clots and prevents from getting
bigger
-does not get rid of a clot
- heparin
- warfarin
heparin - answer--- suppresses intrinsic pathway
- monitor PTT levels every ~4-6 hours
- IV: bolus then continuous drip; unfractional
- SQ: LMW, doesn't require monitoring of PTT levels at low doses
- inactivator: protamine sulfate
- therapeutic action within seconds
- dosing is weight based
low molecular weight heparins - answer--- more predictable and longer
half life
- as effective as unfractionated heparin
- no need to monitor PTT
- SQ only
-ADE: bleeding, thrombocytopenia, neurologic injury
- most common: enoxaparin (lovenox)
solved & updated 2025-2026(latest version verified
for accuracy)
ferrous sulfate - answer--WHY: treatment for IDA
MOA: Replaces serum iron concentration for hemoglobin production
ADE: constipation, darkened stool, staining of teeth, NVD
CI: children toxicity, hemochromatosis, peptic ulcers
D-D: antacids, tetracyclines, ascorbic acid
cyanocobalamin (synthetic form of B12) - answer--WHY: pernicious
anemia, essential for cell growth and division - necessary for myelin
sheath
MOA: replacement of essential vitamin B12
ADE: NVD, injection site reaction, itching
CI: alleries, thickened blood
folic acid (vitamin B9) - answer--WHY: folic acid deficiency anemia,
prophylaxis during pregnancy (prevent neural tube defects)
MOA: water soluble, essential for cell growth and division, replacement
of essential vitamin
ADE: NVD, no known because it is something we already have
CI: allergy, methotrexate
,hydroxyurea (droxia) - answer--WHY: sickle cell anemia, increase fetal
hemoglobin in the bone marrow
MOA: increase fetal hemoglobin in the bone marrow
ADE: NVD, HA, disorientation, chills, increase risk of cancer, bone
marrow suppression
CI: allergy, severe anemia / leukopenia, pregnancy, liver/kidney
impairment
D-D: warfarin, uricosuric agents
epoetin alfa (Epogen), erythropoiesis stimulating agent - answer--WHY:
treat anemia of chronic disease, reduce the need for pRBC transfusions
MOA: stimulates bone marrow to make more RBCs (erythropoiesis)
ADE: seizures, HA, dizzy, NVD, HTN, edema, chest pani
CI: uncontrolled HTN
D-D: do not mix with other drugs
antihemophilic - answer--WHY: replace factor VIII in patients with
hemophilia A, prevent blood loss from injury, surgery or to treat
disorder
MOA: replaced blood clotting factors - genetically missing or low
ADE: HA, flushing, chills, lethargy, NV, site reaction
CI: allergy, inhibitors of factor VIII, factor IX with liver disease, lactation
, antiocoagulants - answer---prevents clots and prevents from getting
bigger
-does not get rid of a clot
- heparin
- warfarin
heparin - answer--- suppresses intrinsic pathway
- monitor PTT levels every ~4-6 hours
- IV: bolus then continuous drip; unfractional
- SQ: LMW, doesn't require monitoring of PTT levels at low doses
- inactivator: protamine sulfate
- therapeutic action within seconds
- dosing is weight based
low molecular weight heparins - answer--- more predictable and longer
half life
- as effective as unfractionated heparin
- no need to monitor PTT
- SQ only
-ADE: bleeding, thrombocytopenia, neurologic injury
- most common: enoxaparin (lovenox)
